Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer

19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer

19 February 2025 - NICE has published final evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin ...

Read more →

Petosemtamab granted breakthrough therapy designation by the US FDA for first-line PD-L1 positive head and neck squamous cell carcinoma

18 February 2025 - This marks the second breakthrough therapy designation for petosemtamab in head and neck squamous cell carcinoma. ...

Read more →

Innovent receives second fast track designation from the US FDA for IBI363 (PD-1/IL-2α-bias bipspecific antibody fusion protein) in squamous non-small cell lung cancer

17 February 2025 - Innovent Biologics announced that its first in class PD-1/IL-2α-bias bi-specific antibody fusion protein, IBI363, has received its ...

Read more →

FDA approves vimseltinib for symptomatic tenosynovial giant cell tumour

14 February 2025 - Today, the FDA approved vimseltinib (Romvimza, Deciphera Pharmaceuticals), a kinase inhibitor, for adult patients with symptomatic ...

Read more →

Keytruda gets expanded coverage for 11 indications at cancer disease panel

13 February 2025 - After nearly two years of stalled discussions, the Keytruda (pembrolizumab) reimbursement expansion debate has finally begun. ...

Read more →

Medical imaging agent gozetotide approved for diagnosis of prostate cancer

12 February 2025 - Gozetotide binds to the cancer cells with prostate-specific membrane antigen on their surface, making them visible during ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine (final guidance)

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

OnCusp Therapeutics receives FDA fast track designation for CUSP06 for the treatment of platinum-resistant ovarian cancer

12 February 2025 - OnCusp Therapeutics today announced that the US FDA has granted fast track designation to CUSP06, a cadherin-6 ...

Read more →

FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma

12 February 2025 - On 11 February 2025, the FDA approved brentuximab vedotin (Adcetris, Seagen) in combination with lenalidomide and a ...

Read more →

Health Canada approves Merck's Keytruda (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

11 February 2025 - Approval is based on the Phase 3 KEYNOTE-671 trial. ...

Read more →

FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection

11 February 2025 - Today, the FDA approved mirdametinib (Gomekli, SpringWorks Therapeutics), a kinase inhibitor, for adult and paediatric patients ...

Read more →

Linvoseltamab BLA accepted for FDA review for the treatment of relapsed/refractory multiple myeloma

11 February 2025 - FDA decision expected by 10 July 2025. ...

Read more →

Gilead’s breast cancer treatment Trodelvy passes drug reimbursement panel

7 February 2025 - Gilead's triple negative breast cancer treatment Trodelvy (trastuzumab govitecan) had surmounted a significant hurdle for health ...

Read more →